Melanie-Rose Brown, senior director of regulatory affairs at Clinigen, discusses the pre-empting and preventing the shockwaves of drug shortages.
Drug shortages happen. Despite industry’s best efforts to establish and maintain robust supply chains, shortages must be considered ‘expected events’ and increasingly our regulators require us to be ready to respond.